Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

Fig. 3

Bar plot of post-TREnd TTF in patients who received subsequent ET, scaled on a median value. Abbreviations: TTF = time to treatment failure. ET = endocrine therapy. AIs = aromatase inhibitors. mTORi = mTOR inhibitors. Values in y-axis are the logarithm of the relationship between single patient and median duration; 0 represents the median value of TTF. Dotted line: value of 3rd quartile (4.7 months). Gray columns denote patients who achieved clinical benefit shown on trial; white column: no clinical benefit demonstrated on trial. Hatched-lines column: denotes > 1 previous line of ET received before entering into the TREnd study

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us